Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago. These ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

Sage Therapeutics has left its view of Biogen's ... last year's $1.1 billion takeover of immunology player HI-Bio – but does not need to rush into a deal. Biogen has been under pressure from ...

February 05, 2025--(BUSINESS WIRE)--Quince Therapeutics ... and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq ... at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m ...

Quince Therapeutics ... Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event ...

Ferguson, MD, as its new Chief Medical (TASE:PMCN ... is based on a press release statement from Cadrenal Therapeutics, Inc. and does not include any speculative content or unverified claims.

SOURCE Carisma Therapeutics Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to ...